Statement on CMS Specialty Tier and Generic/Biosimilar Utilization Measures Proposal – Medicare Advantage/Part D NPRM and Advance Notice

Wednesday February 5, 2020

“CMS’ proposal for a separate preferred specialty tier is a very welcome and significant step that will encourage greater generic and biosimilar adoption for America’s patients. Limiting this tier to lower-cost FDA-approved generic and biosimilar specialty medicines would immediately increase access and savings for seniors and taxpayers alike. Moreover, we applaud CMS’s stated goal to adopt quality measures in the Part D program that reward health plans for increasing generic and biosimilar utilization.”

ATTRIBUTE TO: Christine Simmon, Executive Director

MEDIA CONTACT:
Rachel Schwartz
202.249.7147

 


About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at www.accessiblemeds.org.

Stay Informed About Key Industry Issues

 


Let’s Connect

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:

 

 

October 21–23, 2024 | Rockville, MD

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.